RxDoctor Payments DataLook up a doctor →

William Sharfman, MD

Medical Oncology · Lutherville, MDNPI 1760413652

Payments from drug & device makers

$7,167,184in general payments, 2019–2025

Across 306 payments — averaging $23,422 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$3.9M
  • E.r. Squibb & Sons, L.L.C.$1.3M
  • Novartis$979K
  • Genentech, Inc.$525K
  • Astrazeneca UK Limited$409K
  • Iovance Biotherapeutics, Inc.$18K
  • plus $24K from 12 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,167,184 in reported general payments places this provider in the 95th percentile of 180 medical oncology providers in Maryland.

See all medical oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$14,537,580
Medicare patients
558
Services billed
326,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Lutherville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →